Anal - Karzinom: Studien | ||
Radiance |
Standardbehandlung: Radiochemotherapie mit 5-FU/Mitomycin C +- Durvalumab | Deutsche Krebshilfe, AstraZeneca |
4-armige Studie: Induktionschemotherapie oder Hochdosisboost verbessern das Ergebnis nicht signifikant. | ||
RTOG-05-29 |
Phase II evaluation of dose-painted IMRT in combination with 5-Fluorouracil and Mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal | |
RTOG-98-11 |
Radiation with continuous infusion of fluorouracil plus cisplatin has been evaluated, as seen in the RTOG-9811 trial. [14] | |
RTOG-92-08 |
The optimal dose of radiation with concurrent chemotherapy to optimize local control and minimize sphincter toxic effects has been studied in the RTOG-9208 trial, for example, and appears to be in the 45 Gy to 60 Gy range. (8) | |
RTOG-83-14 |
Chemotherapy concurrent with lower-dose radiation therapy as evidenced in the RTOG-8314 trial, for example, has a 5-year survival rate in excess of 70% with low levels of acute and chronic morbidity, and few patients req | |
Quellen |
1.) Leichman L, Nigro N, Vaitkevicius VK, et al.: | |
Impressum Zuletzt geändert am 31.12.2022 21:43